多发性骨髓瘤患者诊断时是否需要骨髓环钻活检？

IF 2.7 4区医学 Q2 HEMATOLOGY Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-04-01 Epub Date: 2024-12-07 DOI:10.1016/j.clml.2024.12.004

Ana Gea , Tatiana Fernández , Sara Fernández-Luis , Juan J. Domínguez-García , Irene Francés , Ana Tobalina , Rodrigo Cantera , Julia Bannatyne , Irene Gorostidi , María Oviedo , Juan M. Cerezo , Raquel García , Andrés Insunza , Carmen Montes-Gaisán , Aránzazu Bermúdez , Santiago Montes-Moreno , Montserrat Briz , Enrique M. Ocio

{"title":"多发性骨髓瘤患者诊断时是否需要骨髓环钻活检？","authors":"Ana Gea , Tatiana Fernández , Sara Fernández-Luis , Juan J. Domínguez-García , Irene Francés , Ana Tobalina , Rodrigo Cantera , Julia Bannatyne , Irene Gorostidi , María Oviedo , Juan M. Cerezo , Raquel García , Andrés Insunza , Carmen Montes-Gaisán , Aránzazu Bermúdez , Santiago Montes-Moreno , Montserrat Briz , Enrique M. Ocio","doi":"10.1016/j.clml.2024.12.004","DOIUrl":null,"url":null,"abstract":"<div><div>Multiple myeloma (MM) diagnosis requires ≥10% plasma cell (PC) infiltration in the bone marrow (BM), detected by bone marrow aspiration (BMA) or biopsy (BMB). We evaluated the concordance of these 2 techniques in 189 patients. In 43 cases (23%), the techniques were discordant, 10 due to poor sample quality. In the remaining 33 patients, BMB diagnosed MM, while BMA detected < 10% PC, being symptomatic in 16 patients and smouldering (SMM) in 17. Without an initial BMB, 11% would have been misdiagnosed; and 12% of symptomatic patients would require a second BMA or BMB for strict diagnosis according to current criteria.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 4","pages":"Pages e210-e213"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is Bone Marrow Trephine Biopsy Necessary in Multiple Myeloma Patients at Diagnosis?\",\"authors\":\"Ana Gea , Tatiana Fernández , Sara Fernández-Luis , Juan J. Domínguez-García , Irene Francés , Ana Tobalina , Rodrigo Cantera , Julia Bannatyne , Irene Gorostidi , María Oviedo , Juan M. Cerezo , Raquel García , Andrés Insunza , Carmen Montes-Gaisán , Aránzazu Bermúdez , Santiago Montes-Moreno , Montserrat Briz , Enrique M. Ocio\",\"doi\":\"10.1016/j.clml.2024.12.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Multiple myeloma (MM) diagnosis requires ≥10% plasma cell (PC) infiltration in the bone marrow (BM), detected by bone marrow aspiration (BMA) or biopsy (BMB). We evaluated the concordance of these 2 techniques in 189 patients. In 43 cases (23%), the techniques were discordant, 10 due to poor sample quality. In the remaining 33 patients, BMB diagnosed MM, while BMA detected < 10% PC, being symptomatic in 16 patients and smouldering (SMM) in 17. Without an initial BMB, 11% would have been misdiagnosed; and 12% of symptomatic patients would require a second BMA or BMB for strict diagnosis according to current criteria.</div></div>\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\"25 4\",\"pages\":\"Pages e210-e213\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2152265024024406\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265024024406","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

多发性骨髓瘤（MM）的诊断需要骨髓（BM）浆细胞（PC）浸润≥10%，通过骨髓穿刺（BMA）或活检（BMB）检测。我们在189例患者中评估了这两种技术的一致性。在43例（23%）中，技术不一致，10例是由于样本质量差。在其余33例患者中，BMB诊断为MM， BMA检出< 10% PC， 16例有症状，17例有闷烧（SMM）。如果没有最初的BMB， 11%的人会被误诊；12%有症状的患者需要第二次BMA或BMB才能根据现行标准进行严格诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Is Bone Marrow Trephine Biopsy Necessary in Multiple Myeloma Patients at Diagnosis?

Multiple myeloma (MM) diagnosis requires ≥10% plasma cell (PC) infiltration in the bone marrow (BM), detected by bone marrow aspiration (BMA) or biopsy (BMB). We evaluated the concordance of these 2 techniques in 189 patients. In 43 cases (23%), the techniques were discordant, 10 due to poor sample quality. In the remaining 33 patients, BMB diagnosed MM, while BMA detected < 10% PC, being symptomatic in 16 patients and smouldering (SMM) in 17. Without an initial BMB, 11% would have been misdiagnosed; and 12% of symptomatic patients would require a second BMA or BMB for strict diagnosis according to current criteria.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.